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ABSTRACT Toxoplasma gondii is a protozoan parasite that causes lifelong chronic
infection that can reactivate in immunocompromised individuals. Upon infection, the
replicative stage (tachyzoite) converts into a latent tissue cyst stage (bradyzoite).
Like other apicomplexans, T. gondii possesses an extensive lineage of proteins called
ApiAP2s that contain DNA-binding domains first characterized in plants. The func-
tion of most ApiAP2s is unknown. We previously found that AP2IX-4 is a cell cycle-
regulated ApiAP2 expressed only in dividing parasites as a putative transcriptional
repressor. In this study, we purified proteins interacting with AP2IX-4, finding it to
be a component of the recently characterized microrchidia (MORC) transcriptional
repressor complex. We further analyzed AP2XII-2, another cell cycle-regulated factor
that associates with AP2IX-4. We monitored parallel expression of AP2IX-4 and
AP2XII-2 proteins in tachyzoites, detecting peak expression during S/M phase. Unlike
AP2IX-4, which is dispensable in tachyzoites, loss of AP2XII-2 resulted in a slowed
tachyzoite growth due to a delay in S-phase progression. We also found that
AP2XII-2 depletion increased the frequency of bradyzoite differentiation in vitro.
These results suggest that multiple AP2 factors collaborate to ensure proper cell cy-
cle progression and tissue cyst formation in T. gondii.
IMPORTANCE Toxoplasma gondii is a single-celled parasite that persists in its host
by converting into a latent cyst stage. This work describes a new transcriptional fac-
tor called AP2XII-2 that plays a role in properly maintaining the growth rate of repli-
cating parasites, which contributes to signals required for development into its dor-
mant stage. Without AP2XII-2, Toxoplasma parasites experience a delay in their cell
cycle that increases the frequency of latent cyst formation. In addition, we found
that AP2XII-2 operates in a multisubunit complex with other AP2 factors and chro-
matin remodeling machinery that represses gene expression. These findings add to
our understanding of how Toxoplasma parasites balance replication and dormancy,
revealing novel points of potential therapeutic intervention to disrupt this clinically
relevant process.
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Toxoplasma gondii, an obligate intracellular apicomplexan parasite of medical andveterinary interest, can infect almost all warm-blooded animals and is present in
one-third of the human population. The complex life cycle of T. gondii involves multiple
warm-blooded hosts and different developmental forms, including asexual and sexual
stages. The sexual cycle takes place exclusively in the gut of felines, the definitive hosts
for the life cycle, which consequently excrete infectious oocysts into the environment
(1). The asexual phase of the life cycle is comprised of replicating tachyzoites and
quiescent bradyzoites. Upon infection, the parasites increase their biomass and dis-
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seminate throughout the body as tachyzoites, which subsequently convert into latent
bradyzoites that persist in brain, heart, and skeletal muscle tissue inside intracellular
tissue cysts. The presence of bradyzoite cysts in the meat and organs of infected
animals represents another major route of T. gondii transmission (2).
Despite the high prevalence in humans, acute toxoplasmosis is rarely seen and is
most commonly observed as a reactivated infection in patients with HIV/AIDS or some
other immunocompromised condition (3, 4). Congenital toxoplasmosis can also occur
if tachyzoites traverse the placenta, which can lead to miscarriage or birth defects in
humans, as well as abortion in livestock (5–7). Bradyzoite tissue cysts do not appear to
be cleared effectively by the immune system of the host, nor are they targeted by the
currently approved therapeutics (8–10). The formation of latent bradyzoite cysts is
central to T. gondii pathogenesis and transmission, but the molecular mechanisms
involved in stage conversion are incompletely understood (11, 12).
The hunt for T. gondii transcription factors that coordinate the reprogramming of
the genome required for stage conversion has been challenging due to a striking lack
of conventional master regulators in the parasite genome (13). In 2005, a new family of
proteins that possess a DNA-binding domain related to the Apetala-2 transcription
factors of plants was identified in apicomplexan parasites (14). These proteins are called
ApiAP2 factors, and the T. gondii genome encodes 67 of these proteins (15–17), while
the fellow apicomplexan parasite Plasmodium falciparum has 27 (14). In each parasite,
multiple ApiAP2s have been linked to playing a role in regulating gene expression
during specific developmental stages. For example, Plasmodium AP2-G regulates ga-
metocyte development (18) and AP2-Sp2 regulates gene expression during the sporo-
zoite stage (19). A number of ApiAP2s in T. gondii have been linked to tachyzoite stage
conversion into bradyzoites (20). AP2IX-9 acts as a transcriptional repressor of brady-
zoite genes and restricts commitment to development into in vitro bradyzoite tissue
cysts (20). Like AP2IX-9, AP2IV-3 is upregulated during pH-induced in vitro bradyzoite
differentiation, but acts as a transcriptional activator that likely competes to control
bradyzoite gene expression with AP2IX-9 (21). Knocking out AP2IV-4 resulted in the
expression of a subset of bradyzoite-specific proteins in replicating tachyzoites, which
prevented tissue cyst formation in mice (22).
We previously determined that AP2IX-4 is a cell cycle-regulated factor expressed
exclusively during division of tachyzoites and bradyzoites (23). Genetic knockout of
AP2IX-4 had no discernible effect on tachyzoites, but reduced the frequency of tissue
cyst formation in vitro and in vivo in mice (23). Transcriptional profiling showed that
PruΔap2IX-4 parasites display upregulation of a subset of bradyzoite genes over and
above that seen in parental parasites exposed to alkaline stress, suggesting that it
functions as a repressor of these genes. Despite the upregulation of several key
bradyzoite genes, PruΔap2IX-4 parasites showed a modest decrease in bradyzoite
conversion in culture and in BALB/c mice.
To better understand the role of AP2IX-4, we purified the AP2IX-4 complex in this
study, finding that it associates with the microrchidia (MORC) transcriptional repressor
complex (24). We further interrogated the function of an AP2IX-4-interacting protein,
AP2XII-2, which largely shares its cell cycle expression profile. In contrast to the
dispensable AP2IX-4, tachyzoites lacking AP2XII-2 exhibit a fitness defect in vitro.
Further experiments showed that AP2XII-2 is important for proper progression through
the S-phase of the tachyzoite cell cycle and that its loss increases in vitro bradyzoite
differentiation. These findings shed new light on the complex interplay between
multiple AP2 factors regulating cell cycle and bradyzoite development in T. gondii.
RESULTS
Identification of proteins interacting with AP2IX-4. We previously identified a cell
cycle-regulated ApiAP2 transcription factor called AP2IX-4 (T. gondii ME49_288950
[TGME49_288950]) that is expressed exclusively in dividing parasites (23). Genetic
depletion of AP2IX-4 resulted in dysregulation of stage-specific gene regulation, which
lowered the frequency of bradyzoite tissue cyst formation in vitro and in vivo. To better
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understand the role of AP2IX-4, we engineered RHΔku80 tachyzoites to express en-
dogenous AP2IX-4 protein with a C-terminal 3HA (3 hemagglutinin) tag for use in
immunoprecipitation experiments (AP2IX-4HA) (Fig. 1A). Western analysis of fraction-
ated nuclear and cytosolic extracts revealed that AP2IX-4 is exclusively expressed in the
parasite nucleus (Fig. 1B). Immunoprecipitation from the nuclear fraction using anti-HA
purified a protein of the expected size of 104 kDa (Fig. 1C).
Mass spectrometry and SAINT analysis of proteins coimmunoprecipitating with
AP2IX-4HA included two additional ApiAP2 factors: AP2XII-2 (TGGT1_217700) and
AP2VIIa-3 (TGGT1_205650) (Fig. 2A; see Table S1 in the supplemental material for
complete data set). We also detected proteins interacting with AP2IX-4 that are
associated with transcriptional repressive activity in tachyzoites: histone deacetylase 3
(HDAC3) (TGGT1_227290) and microrchidia, or MORC (TGGT1_305340, formerly
CRC230), and two hypothetical proteins (TGGT1_214140 and TGGT1_275680) (Fig. 2A).
Panel B of Fig. 2 shows a volcano plot generated with P values (log10 P values) and
fold change values (log2 FC) for the 136 protein hits detected from mass spectrometry.
Together, the proteins complexed with AP2IX-4 overlap the recently elucidated mi-
crorchidia (MORC) repressor complex that has been implicated in silencing genes
associated with the T. gondii sexual stages (24). Thus, our findings bolster the obser-
vation that multiple AP2 factors recruit MORC to regulate gene expression and provide
an explanation as to why the loss of AP2IX-4 resulted in the dysregulation of genes (23).
Panel C of Fig. 2 displays the mRNA expression profiles of AP2IX-4 and its interacting
proteins (based on previously published data [22]). AP2IX-4 and AP2XII-2 have nearly
parallel cell cycle-dependent expression patterns that reach their peaks during the S/M
phase of the cell cycle before dropping in G1 phase. These data suggest that AP2IX-4
and AP2XII-2 operate during S/M phase. The mRNA levels of the other proteins pulled
down with AP2IX-4 represented constitutive expression. Although it showed consider-
FIG 1 Endogenously tagged AP2IX-4HA localizes to parasite nucleus. (A) Diagram of T. gondii AP2IX-4HA
protein. aa, amino acids. (B) Nuclear (N) and cytosolic (C) fractions of RHΔku80 parental tachyzoites
(negative control) and RHΔku80 parasites expressing AP2IX-4HA protein were generated for Western blot
analysis using rat anti-HA antibodies. Each blot was reprobed with anti-TgIF2 as a cytosolic marker and
anti-histone H3 as a nuclear marker. (C) Western blot of AP2IX-4 immunoprecipitated from purified
intracellular RHΔku80 tachyzoites via the use of Dynabeads coupled with mouse anti-HA antibodies.
Western blots were probed using rat anti-HA antibody. Tagged AP2IX-4HA migrates at the expected size
of 104 kDa.
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ably lower peptide counts, AP2VIIa-3 is another AP2 factor that purified in the AP2IX-4
interactome that was also identified in the MORC complex (24). AP2VIIa-3 is not cell
cycle regulated (Fig. 2C) and was not analyzed further in this study.
Localization and interaction between AP2IX-4 and AP2XII-2. The single exon of
the AP2XII-2 gene encodes a 195-kDa protein containing 1,431 amino acids and a single
AP2 domain proximal to the C terminus (Fig. 3A). To validate the protein-protein
interaction and study AP2XII-2 further, we endogenously tagged the C terminus of
AP2XII-2 with 3MYC in the RHΔku80 parasites expressing AP2IX-4HA. Immunoblots of
FIG 2 AP2IX-4 core complex in Toxoplasma tachyzoites. (A) Results of mass spectrometry analysis of
endogenously tagged AP2IX-4HA immunoprecipitate from tachyzoites, performed on intracellular para-
sites harvested from infected HFF cells. Two biological replicates were performed for AP2IX-4 immuno-
precipitation experiments. Listed are proteins interacting with AP2IX-4 with probability of interaction as
measured by a pSAINT value of 0.9 or above (see Table S1 for complete data set). Asterisks (*) denote
proteins that were also identified in the MORC complex. ID, identifier; MW, molecular weight. (B) Volcano
plot representing proteins copurified in the AP2IX-4HA pulldown and identified by mass spectrometry,
displaying statistical significance (P value) and fold change and each hit. The x axis plots the log2 fold
change (HA/IgG), and the y axis demonstrates P values (statistical significance) in log10. The horizontal
dashed line indicates the P value (0.05) selected as the significance threshold. (C) Expression of transcripts
for key proteins found in association with AP2IX-4 (source of data: ToxoDB.org). RMA, robust multiarray
average; G1, G1 phase; S, synthesis phase; M, mitosis phase; C, cytokinesis phase.
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these dual-tagged parasites confirmed the presence of both in the nuclear fraction
(Fig. 3B). We performed reciprocal coimmunoprecipitations of AP2IX-4HA and AP2XII-
2MYC followed by Western blotting, which validated their interaction in intracellular
tachyzoites (Fig. 3C and D).
We next monitored the pattern of expression for AP2XII-2MYC by immunofluores-
cence assay (IFA) for comparison to what we had observed previously for AP2IX-4 (23).
To delineate the cell cycle expression profile of AP2XII-2, we costained with established
cell cycle markers, including Inner membrane complex-3 (IMC3) and T. gondii Centrin-1
(TgCentrin-1) (Fig. 4A) (25, 26). Results show that AP2XII-2MYC protein was expressed in
the second half of the cell cycle prior to the start of budding and continued until the
buds were mature, in agreement with mRNA profiling results (Fig. 2C). This protein
expression pattern is consistent with a cell cycle timing that begins in S phase and
continues into mitosis, with the factor downregulated after nuclear division (very early
G1 period). Expression of AP2XII-2 diminishes before the onset of C-phase (cytokinesis);
this is in contrast to AP2IX-4, which can be detected through to the end of cytokinesis
(23). By costaining with TgCentrin-1, we identified distinct parasite vacuoles in either G1
or S-phase of the cell cycle in the same field; note that AP2XII-2 is detected in parasites
only during S-phase and not in G1 (Fig. 4B). By staining with anti-MYC, anti-HA, and
anti-IMC3, we were able to show that both AP2 proteins are coexpressed during
S-phase of the cell cycle (Fig. 4C). Altogether, these data support an intimate interaction
between AP2IX-4 and AP2XII-2 during parasite division.
Conditional knockdown of AP2XII-2 slows parasite replication. To further inves-
tigate the role of AP2XII-2 in T. gondii, we attempted to genetically ablate the endog-
enous AP2XII-2 gene. Both conventional allelic replacement using homologous recom-
bination and CRISPR/Cas9 approaches yielded no viable parasites, suggesting that
FIG 3 Interaction of AP2IX-4 and AP2XII-2. (A) Schematic representation of candidate interacting protein
AP2XII-2 endogenously tagged with a c-MYC epitope. (B) Western blot of fractionated parasites showing
that both AP2XII-2MYC and AP2IX-4HA localize to the parasite nucleus. The blot was reprobed with
anti-TgIF2 and anti-histone H3 as cytosolic and nuclear markers, respectively. (C) Coimmunoprecipita-
tion (Co-IP) confirmed the interaction between AP2XII-2MYC and AP2IX-4HA in tachyzoites. (Top panel) IP
was performed with anti-HA to pull down AP2IX-4HA; probing with anti-MYC detected AP2XII-2MYC in the
IP. (Bottom panel) The membrane was reprobed with anti-HA. (D) Reciprocal Co-IP further confirmed the
interaction; in this case, the IP was performed with anti-MYC to pull down AP2XII-2MYC. The top panel
shows that probing performed with anti-MYC detected AP2XII-2MYC. The bottom panel shows the results
of reprobing with anti-HA, which detected AP2IX-4HA in the IP.
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AP2XII-2 is essential in tachyzoites. A genome-wide CRISPR survey assigned this AP2 a
score of 1.16, suggestive that the loss of AP2XII-2 compromises fitness (22).
We therefore pursued an indole-3-acetic acid (IAA)-inducible degradation (AID)
strategy that would allow a conditional knockdown of AP2XII-2 protein through the
addition of IAA (27). We endogenously tagged AP2XII-2 with a C-terminal AID-3HA
tag in RH-TIR1-3Flag Δku80 parasites (27) (Fig. 5A and B). A clone was isolated in
which AP2XII-2AID-HA protein was undetectable within 15 min after inclusion of IAA in
the culture medium (Fig. 5C). To determine the role of AP2XII-2 in parasite viability, we
performed a standard plaque assay in the presence of IAA. The loss of AP2XII-2 resulted
in smaller plaque sizes than were seen with the parental parasites, although there was
no change in plaque number (Fig. 5D to F). These results suggest a defect in parasite
replication rather than invasion. To confirm this idea, we cultured parasites in 500 M
FIG 4 Immunofluorescence assay of AP2IX-4 and AP2XII-2 during cell cycle. (A) RHΔku80 (RH) parasites expressing
endogenously tagged AP2XII-2MYC were probed with antibodies to c-MYC (green) and IMC3 (red), the latter of which helps
detect budding daughter parasites. AP2XII-2MYC was detectable in the S and S/M phases but disappeared before the onset
of cytokinesis (C). DAPI (blue) was used as a nuclear stain. The four rows show parasites in different stages of the cell cycle.
Scale bar  2 m. (B) To more closely examine the expression of AP2XII-2MYC during cell cycle, an IFA was performed using
antibodies to c-MYC (green) and Centrin-1 (red). Parasites in G1 contain single centrosomes, whereas those in S-phase are
duplicated. Arrows indicate centrosomes. Scale bar  2 m. (C) Triple-labeled IFA to determine cell cycle expression
patterns for each AP2 factor. AP2XII-2MYC (green) and AP2IX-4HA (red) colocalized in S-phase. IMC3 (yellow) and larger
nuclei (DAPI, blue) identify parasites in S-phase. Scale bar  2 m.
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FIG 5 Conditional knockdown of AP2XII-2. (A) Schematic representation of AP2XII-2 endogenously tagged with AID-HA
at the C terminus. (B) Western blot showing expression of AP2XII-2AID-HA in RH-TIR1 parental parasites at the expected size
(250 kDa). SAG1 serves as a loading control. (C) Western blot probed with anti-HA to monitor AP2XII-2AID-HA protein levels
over a time course after addition of 500 M IAA. SAG1 was used as a loading control. (D) Representative plaque assay
image of AP2XII-2AID-HA parasites treated with 500 M IAA or vehicle (ethanol [EtOH]) for 6 days, showing the presence of
smaller plaque sizes when AP2XII-2 was depleted. (E) Number of plaques generated for parental parasite (TIR1) and
AP2XII-2AID-HA in the presence () or absence (-) of IAA 6 days postinfection. Each dot represents average of each
experiment ( standard deviation [SD], n  3). Unpaired Student’s t test was performed for analysis; ns, not significant. (F)
The degree of host cell monolayer lysis was quantified for the plaque assays. Each dot represents the average of results
from each experiment ( SD, n  3). Unpaired Student’s t test was performed for analysis. ns, not significant; *, P  0.05.
(G) AP2XII-2AID-HA parasites were grown in the presence of 500 M IAA or vehicle (EtOH) for 24 h, forcibly lysed from host
cells, and then allowed to invade a new HFF monolayer for 30 min for attachment and invasion assay. The data represent
means  SD (n  3). Data were analyzed using two-way analysis of variance (ANOVA) and Tukey’s multiple-comparison
test. ns  not significant. (H) Doubling assays were performed to assess replication of AP2XII-2AID-HA parasites in the
presence of 500 M IAA or vehicle (EtOH). Parasites were counted from 100 random vacuoles following 24 h of infection.
The numbers of parasites were plotted as percentages of the total number of parasite vacuoles. The values represent
means  SD (n  3). Two-way ANOVA with Tukey’s multiple-comparison test was performed. ****, P  0.0001; ns  not
significant.
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IAA for 24 h and then subjected them to syringe lysis and filter purification for an
attachment and invasion assay (27). We found that AP2XII-2 depletion had no effect on
invasion or attachment of parasites (Fig. 5G). We also conducted a parasite counting
assay in the presence of IAA or vehicle (ethanol [EtOH]), finding that replication rates
were significantly lower without AP2XII-2 (Fig. 5H). AP2XII-2AID-HA parasites treated with
IAA for 24 h contained more vacuoles with only 8 parasites and fewer vacuoles with 16
parasites.
Loss of AP2XII-2 delays S-phase and increases bradyzoite differentiation. We
further examined the replication defect seen in AP2XII-2-depleted parasites by centro-
some counting. Normally, in an asynchronous parasite population in culture, 50% of
parasites are in G1 phase (single centrosome) and 50% of parasites are in S-phase
undergoing DNA replication (duplicated centrosome) (28). Without IAA, the AP2XII-
2AID-HA parasites showed a 50/50 split of single and duplicated centrosomes within the
population; in contrast, when AP2XII-2AID-HA parasites were treated with IAA, 75% of
the population exhibited duplicated centrosomes, supporting a delay in S-phase of the
cell cycle (Fig. 6A and B).
To further characterize the cell cycle defect, we compared the lengths of the S-phase
in AP2XII-2AID-HA parasites with or without IAA by calculating doubling time from
average vacuole size as described previously (29). The parasites expressing AP2XII-2 had
a doubling time of 7.4 h, whereas those depleted of AP2XII-2 showed an increase in the
doubling time to 9.0 h (Fig. 6C). We then determined the percentages of parasites in the
different cell cycle stages using IFAs probed with markers for the centrosome (anti-
Centrin-1) and daughter cell budding (anti-IMC3) as described previously by Szatanek
et al. (30). Parasites containing a single centrosome without daughters are in G1,
parasites with duplicated centrosomes without daughters are in S phase, and parasites
with duplicated centrosomes and budding daughters are undergoing cytokinesis (C). In
the parasites expressing AP2XII-2, approximately 50% were in G1, 35% were in S, and
14% were in C. In parasites depleted of AP2XII-2, this ratio was approximately 25% (G1),
65% (S), and 10% (C). We calculated the duration of G1 and S phase based on the
doubling times and percentages of parasites in different stages of the cell cycle. Results
show that the length of S-phase in parasites lacking AP2XII-2 was 5.85 h compared to
2.6 h when AP2XII-2 was expressed (Fig. 6D).
It was shown previously that the initiation of bradyzoite differentiation and tissue
cyst formation requires a slowing in DNA replication, delayed S-phase, and lengthening
of G1 phase (31, 32). Given the delay in S-phase produced by depletion of AP2XII-2, we
examined whether there is also an increased frequency of bradyzoite development. To
do so, we endogenously tagged AP2XII-2 with AID-HA in type II ME49-TIR1 parasites
(33). A clone was isolated in which AP2XII-2AID-HA protein was undetectable after
inclusion of IAA in the culture medium (Fig. 7A). The deficiency in plaque size shown
by ME49 AP2XII-2AID-HA parasites treated with IAA was the same as that shown by their
RH counterparts (data not shown). We then examined the frequency of tissue cyst
formation of ME49 AP2XII-2AID-HA parasites incubated under conditions of alkaline
stress with or without IAA (Fig. 7B). After 3 days in alkaline media without IAA, 50%
of parasite vacuoles were staining positive with the cyst wall marker Dolichos. However,
AP2XII-2AID-HA parasites maintained in media with IAA displayed 88% conversion into
bradyzoite cysts (Fig. 7B and C). No overt changes in the size or morphology of the cysts
formed were evident. Type II ME49-TIR1 parasites did not show any difference in
differentiation when incubated in the presence of IAA under alkaline stress conditions
(data not shown), as previously reported (33). It should be noted that IAA did not
enhance bradyzoite formation at day 1 or day 2, supporting the idea that IAA is not a
contributing factor in the increased frequency of tissue cyst formation.
Consistent with the restricted cell cycle expression of AP2XII-2 in tachyzoites, this
factor was detected in replicating parasites only following alkaline medium stress
(Fig. 7B), an expression pattern also shown by its interacting AP2, AP2IX-4 (23). Also
similarly to AP2IX-4, AP2XII-2 expression levels decreased during the initial stages of
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bradyzoite differentiation and then increased again. Upon addition of alkaline stress,
AP2XII-2 expression levels dropped from 50% to 20% within the parasite population,
but by day 3, AP2XII-2 was present in 55% of bradyzoite cysts (Fig. 7D).
Together, these results indicate that AP2XII-2 is an important contributor to timely
progression through S-phase of the cell cycle and that its loss slows tachyzoite
replication and promotes bradyzoite differentiation.
DISCUSSION
In the present work, we report that AP2IX-4 can associate with the T. gondii MORC
transcriptional repressor complex during its expression in S/M phases of the tachyzoite
cell cycle. We also characterized a previously undescribed ApiAP2 interacting with
AP2IX-4, AP2XII-2, which knockdown experiments revealed to be important for proper
progression through S-phase.
There is evidence that commitment to differentiation may occur during the S/M
phase of the tachyzoite cell cycle (34); it requires transient slowing of growth (35),
FIG 6 AP2XII-2 depletion results in a delay in S-phase of cell cycle. (A) A total of 100 parasite vacuoles in 10 random
fields were counted for single or duplicated centrosomes in 3 biological replicates. Tukey’s multiple-comparison
test was performed with two-way ANOVA. Error bars represent standard deviations of the means; ****, P  0.0001;
ns  not significant. (B) Representative IFAs of AP2XII-2AID-HA parasites with or without IAA showing single (S) and
duplicated (D) centrosomes as stained by anti-Centrin-1 (green). Scale bar 10 m. (C) The number of parasites per
vacuole was counted at each indicated time point for 100 randomly chosen vacuoles to calculate doubling time of
AP2XII-2AID-HA parasites with or without IAA. Error bars represent mean  SD (n  3). The exponential growth equation
was used to calculate the doubling time in GraphPad Prism software as described previously (29). (D) The percentage
of AP2XII-2AID-HA parasites (with [] or without [-] IAA) in various stages of the cell cycle was determined as described
in the text. Doubling times (DT) in hours determined as described for panel C are also shown.
AP2XII-2 Contributes to Toxoplasma Cell Cycle
September/October 2020 Volume 5 Issue 5 e00542-20 msphere.asm.org 9
delayed S-phase, and lengthening of the G1 phase (32). Bradyzoite cyst formation
represents a complex developmental pathway that requires a cascade of events in
which multiple ApiAP2 transcription factors appear to be involved (11). Research is just
beginning to reveal the sophistication of the ApiAP2 network, which possesses both
transcriptional repressors and activators. AP2IX-9, AP2IV-4, and AP2IX-4 repress transcrip-
tion of bradyzoite genes and impair tissue cyst formation (20–23), whereas AP2IV-3 appears
to activate transcription (21). Given their evolutionary origin, some members of the ApiAP2
family may exhibit features found in the plant kingdom, which has AP2 domain proteins
classified as active and passive transcription factors (36). Passive repressors may compete
with activators to dampen transcription, allowing a fine-tuning of gene expression (36). In
addition to ApiAP2s, a “master regulator” transcription factor termed BFD1 (Bradyzoite
Formation Deficient-1), which harbors a myb-like DNA-binding domain, has recently been
described that is essential for tissue cyst formation (37). Both BFD1 and MORC bind the
promoter of AP2IX-9, as well as other AP2 factors; MORC also associates with additional AP2
factors, many of which have yet to be characterized. How the various AP2 factors interplay
with these other transcriptional regulators to affect gene expression remains an important
focus for future investigation.
Our report also adds to the growing evidence indicating that at least some ApiAP2s
FIG 7 AP2XII-2 depletion leads to increased bradyzoite differentiation. (A) Western blot with anti-HA confirms the
depletion of AP2XII-2AID-HA in type II ME49-TIR1 parasites. SAG1 was used as a loading control. Parasites were
treated with 500 M IAA or vehicle (EtOH) for 24 h. (B) Type II AP2XII-2AID-HA tachyzoites were induced to
differentiation with alkaline pH 8.2 for 3 days in the presence of 500 M IAA or vehicle (EtOH). Differentiating
parasites were stained with anti-HA (red) and Dolichos lectin (DBA, green) to visualize tissue cyst wall. DAPI (blue)
was included to highlight nuclei. Scale bar  10 m. (C and D) Graphical depiction of data from panel B. A total
of 100 random vacuoles were counted for Dolichos (DBA)-positive (C) and HA-positive (D) staining, shown to the
right of the IFA panels. n  3 for control and 500 M IAA-treated parasites. Error bars represent standard errors of
the means; ns  not significant; *, P  0.05 (unpaired two-tailed Student’s t test).
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coordinate transcriptional regulatory activities through interactions with chromatin
remodeling machinery. We recently reported that the essential histone acetyltrans-
ferase (HAT) GCN5b operates in a multisubunit complex with at least two ApiAP2
factors, AP2IX-7 and AP2XII-4, to activate gene expression (38). In the current study, we
found that AP2IX-4 and APXII-2 interact with the recently described MORC complex,
which contains transcriptional repressive proteins, including histone deacetylase
HDAC3 (24). Identifying AP2IX-4 as an interactor with MORC validates our previous
observation that loss of AP2IX-4 results in upregulation of a subset of bradyzoite genes
(23). It is likely that other ApiAP2s acting as repressors or activators mediate these
regulatory events through collaboration with HDACs or HATs, respectively.
AP2IX-4 is a cell cycle-regulated factor with peak expression in S/M phase (23). The
AP2IX-4 complex that we isolated contained two additional uncharacterized ApiAP2s,
AP2XII-2 and AP2VIIa-3. The AP2XII-2 cell cycle expression pattern is highly similar to
that of AP2IX-4, which we confirmed by IFA after tagging the endogenous protein. Like
AP2IX-4, AP2XII-2 is a nuclear protein with peak expression during the S/M phase.
However, AP2XII-2 expression decreases before the onset of C-phase whereas AP2IX-4
expression remains through cytokinesis. These findings suggest that the two AP2s may
collaborate during tachyzoite division but that AP2IX-4 may have another, independent
role toward the end of the process. Curiously, AP2IX-4 is dispensable in tachyzoites but
loss of its interacting partner AP2XII-2 impairs replication due to a delay in S-phase,
which likely explains the enhanced bradyzoite differentiation seen when AP2XII-2 is
knocked down. AP2XII-2 may be able to compensate for the loss of AP2IX-4, but
AP2IX-4 cannot replace the function of AP2XII-2. We noted that knockdown of AP2XII-2
did not affect AP2IX-4 transcript levels (data not shown), but potential changes in
protein levels could not be assessed with the reagents in hand. It is also possible that
AP2XII-2 has an additional function in the cell cycle that is independent of AP2IX-4. The
precise role of AP2XII-2 in facilitating progress through S-phase is an important subject
for future investigation. The roles performed by these two AP2 factors are likely to
diverge under stress conditions or during bradyzoite development as knockout of
AP2IX-4 impaired in vitro differentiation whereas knockdown of AP2XII-2 enhanced it.
As we observed for AP2IX-4 (23), the expression levels of AP2XII-2 protein dropped
during the early stages of bradyzoite differentiation. AP2XII-2 was detectable in 20%
of bradyzoite cysts at day 1 and day 2 postinduction but was present in 	55% of
bradyzoite cysts by day 3 (Fig. 7B). Since the S/M period becomes more pronounced
during bradyzoite differentiation, the increase in AP2XII-2-positive parasite numbers
further supports the idea of a defined cell cycle context for commitment to bradyzoite
differentiation. We found previously that AP2IX-4 is present only in dividing parasites
within cysts, and this is likely to be the case for AP2XII-2. We suspect that these in vitro
bradyzoites are immature and still undergoing some level of cell division, which
requires these two ApiAP2s for proper progression through the cell cycle. Our findings
underscore the links between cell cycle progression, parasite division, and the com-
mitment to bradyzoite differentiation and bolster the concept that cell cycle-regulated
ApiAP2s such as AP2IX-4 and AP2XII-2 work with chromatin remodeling machinery like
MORC to regulate gene expression relevant to cell cycle progression.
MATERIALS AND METHODS
Parasite culture and transfection. The parasite strains used for this study included RHΔhxgprtΔku80
(39), RHΔhxgprtΔku80:AP2IX-4HA (23), and RH and ME49 parasites engineered to express TIR1 for IAA-
mediated protein degradation (27, 33).
Parasites were cultured in human foreskin fibroblast (HFF) cells in Dulbecco’s modified Eagle medium
supplemented with 1% fetal bovine serum, 100 unit/ml penicillin, and 100 g/ml streptomycin. Trans-
fection of parasites was performed as previously described using a 4D-Nucleofector system (Lonza)
and selection for drug resistance 24 h posttransfection (40–42). Transfected parasites were selected
in either 1 M pyrimethamine or 25 g/ml mycophenolic acid plus 50 g/ml xanthine as described
previously (43, 44).
Generation of parasites expressing endogenously tagged AP2IX-4HA and AP2XII-2MYC.
RHΔhxgprtΔku80:AP2IX-4HA (23) parasites were genetically modified to express endogenous AP2XII-2
tagged with MYC at the C terminus. Modification of the endogenous locus of AP2XII-2 was performed
by a genetic knock-in approach using plasmid pLIC-3xMYC-HXGPRT (39). Primers (Fw, 5=-ATCCAATTTA
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ATTAATCTTCTGTGTCCCGGTGG-3=; Rv, 5=-TCCAATTTTAATTAAGCCACTGAGTGGTGAAACA-3=) were used
to amplify 1,975 bp of the AP2XII-2 gene, which was then cloned into the PacI site of pLIC-3xMYC-
HXGPRT plasmid. The resulting construct was linearized and transfected into RHΔhxgprtΔku80:AP2IX-4HA
parasites. Transfected parasites were selected in 25 g/ml mycophenolic acid plus 50 g/ml xanthine,
and independent clones were isolated by limiting dilution.
Generation of parasites expressing endogenously tagged AP2XII-2AID-HA. To generate type I and
type II conditional knockdown strains, specific primers (Fw, 5=-ACCGGGCCCGCTAGCTCTTCTGTGTCCCG
GTGG-3=; Rv, 5=-CGAGCCCTTGCTAGCGCCACTGAGTGGTGAAACA-3=) were used to amplify 1,975 bp of the
AP2XII-2 gene for cloning into the NheI site of pLIC-AID-3xHA-DHFR plasmid. The construct was
linearized and transfected into either RH or ME49-TIR1-expressing parasites (27, 31). Parasites were
selected in 1 M pyrimethamine, and single clones were isolated by limiting dilution. Parasites were
treated with 500 M IAA (Sigma-Aldrich) or vehicle (EtOH) for the indicated period of time to induce
degradation of AID-tagged protein.
Parasite growth assays. For plaque assays, 500 freshly syringe-lysed intracellular parasites were
allowed to invade a confluent monolayer of HFF cells grown in 12-well plates in 500 M IAA or vehicle
(EtOH). Six days postinfection, the infected monolayers were stained with crystal violet stain to determine
host cell lysis as previously described (45).
For doubling assays, purified intracellular parasites were allowed to invade confluent HFF cells for
30 min. After invasion, infected HFF cells were gently washed with culture medium to remove extracel-
lular tachyzoites and fresh medium was added. After 24 h, infected monolayers were fixed with 4%
paraformaldehyde for 10 min at room temperature, incubated in blocking buffer for 30 min, and then
stained with anti-SAG1 antibody (Invitrogen) for 1 h at room temperature. The fixed cells were then
washed with phosphate-buffered saline (PBS) and incubated with secondary goat anti-mouse Alexa Fluor
488 (Invitrogen) for 1 h at room temperature. Cells were mounted with ProLong gold antifade mounting
solution (Invitrogen) containing DAPI (4=,6-diamidino-2-phenylindole). The number of parasites in 100
randomly selected vacuoles was counted at the designated time point (46).
Invasion and attachment assays. Invasion and attachment assays were performed as previously
described (27, 47). Briefly, parasites were allowed to grow in 500 M IAA or vehicle (EtOH) for 24 h and
then purified from host cells via syringe lysis. The parasites were allowed to invade confluent HFF cells
for 30 min prior to fixation with 4% paraformaldehyde (Sigma). Attached parasites were labeled with
mouse anti-SAG1 (Thermo Fisher) and then subjected to permeabilization in 0.1% Triton X-100. Next,
parasites were stained with anti-IMC3 antibody (a gift from Marc-Jan Gubbels) followed by anti-mouse
Alexa Fluor 488 (Invitrogen) and anti-rat Alexa Fluor 594 (Invitrogen). Ten random fields were imaged,
and the number of attached and invaded parasites was counted. Primary antibody dilutions were used
as follows: mouse anti-SAG1 (Thermo Fisher) 1:1,000 and rat anti-IMC3 1:2,000. Secondary Alexa Fluor
antibodies were used at 1:1,000 dilution.
Western blotting. Confluent HFF cells infected with tachyzoites were subjected to syringe lysis 24 h
postinfection and filtered, followed by centrifugation. Parasite pellets were resuspended in NuPAGE lysis
buffer and boiled for 5 min. Parasite lysates (80 g) were separated on a 4% to 12% Tris-acetate
polyacrylamide gradient gel (Invitrogen) and transferred onto polyvinylidene difluoride (PVDF) mem-
branes. Western blotting was performed with the designated antibodies, and the blots were developed
with SuperSignal West Femto sensitivity substrate (Pierce).
Primary antibody dilutions were used as follows: rat anti-HA antibody (Roche) 1:2,000; mouse
anti-MYC (Cell Signaling) 1:5,000; rabbit anti-MYC (Thermo) 1:5,000; rabbit anti-H3 (Sigma) 1:5,000; rabbit
eukaryotic initiation factor 2 (eIF2) 1:20,000 (48); mouse anti-Sag1 (Thermo Fisher) 1:5,000. Secondary
horseradish peroxidase (HRP)-conjugated antibody dilutions were used as follows: goat anti-rat (GE
Healthcare) 1:2,000; goat anti-mouse (Sigma) 1:5,000; goat anti-rabbit (Sigma) 1:5,000.
Immunofluorescence assays (IFA). Parasites growing in confluent HFF cells were fixed in 4%
paraformaldehyde for 10 min followed by washing in PBS three times. Fixed cells were incubated for 1 h
at room temperature in blocking buffer containing 3% bovine serum albumin (BSA) and 0.2% Triton
X-100. The cells were incubated with the designated antibodies in blocking buffer at 4°C overnight
followed by washing in PBS. The cells were then incubated with secondary antibodies coupled to Alexa
Fluor 488/594/568/647 at room temperature for 1 h. The cells were finally washed with PBS and mounted
with ProLong gold antifade mounting solution (Invitrogen) containing DAPI (Invitrogen) and then
visualized using a Nikon Eclipse E100080i microscope. Images were captured with a Hamamatsu
C474295 charge-coupled-device (CCD) camera. Nikon NIS element software was used to analyze and
capture images. Primary antibody dilutions were used as follows: rabbit anti-HA (Cell Signaling) 1:1,000,
rat anti-HA (Roche) 1:1,000, mouse anti-MYC (Cell Signaling) 1:1,000, Toxoplasma anti-Centrin-1 (Kerafast
Inc.) 1:2,000, rat anti-IMC3 (supplied by Marc-Jan Gubbels) 1:2,000. For the visualization of bradyzoite
tissue cyst walls, fluorescein isothiocyanate (FITC)-conjugated Dolichos biflorus lectin (Vector Laborato-
ries) was used at a 1:500 dilution for 1 h at room temperature as previously described (23).
Bradyzoite differentiation assay. In vitro bradyzoite differentiation experiments were performed as
described elsewhere (20, 49, 50). Briefly, parasites were allowed to invade a confluent monolayer of HFF
cells grown in 12-well plates. After 2 h postinvasion, tachyzoite medium (pH 7.0) was replaced with
bradyzoite differentiation medium (pH 8.2), and parasites were grown in the presence of IAA (500 M)
or vehicle (EtOH) for the indicated time periods (20, 49, 50). The medium was changed every 24 h to
maintain pH for parasites undergoing differentiation, with fresh IAA (500 M) or vehicle (EtOH) added.
A hundred random fields were selected in a blind under phase contrast, and then the numbers of
parasite vacuoles were counted for DBA and HA positivity by changing the corresponding channels. If
any parasites within the vacuole contained HA signal, the result was scored as positive.
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Subcellular fractionation. Purified parasite pellets were resuspended in 1 ml low-salt buffer (50 mM
HEPES-NaOH [pH 7.5], 20% glycerol, 10 mM NaCl, 0.1% NP-40) and incubated at 4°C for 10 min followed
by centrifugation at 2,500  g for 15 min. The supernatant was collected as the cytoplasmic fraction. The
pellet containing the nuclei was resuspended in high-salt extraction buffer (50 mM HEPES-NaOH [pH 7.5],
20% glycerol, 420 mM NaCl, 0.4% NP-40) for 10 min at 4°C with intermittent stirring followed by brief
sonication (5 rounds, 10 s each). Following centrifugation at 13,000  g for 30 min, the cleared nuclear
fraction supernatant was collected. All buffers were supplemented with cOmplete Mini, EDTA-free
protease inhibitor cocktail (Roche, catalog no. 11 836 170 001).
Purification of the AP2IX-4 complex. RHΔhxgprt parasites endogenously expressing AP2IX-4HA or
AP2IX-4HA/AP2XII-2MYC were used to pull down the core AP2IX-4 complex. Large-scale tachyzoite cultures
were grown for 24 h in HFF cells, followed by scraping the infected monolayers and syringe lysis through
a 25-gauge needle to isolate free tachyzoites. Parasites were further purified through a 3-m-pore-size
membrane filter and centrifuged at 4°C for 10 min at 700  g. The parasite pellets were lysed in low-salt
buffer (50 mM HEPES-NaOH [pH 7.5], 20% glycerol, 10 mM NaCl, 0.1% NP-40) for 10 min on ice followed
by centrifugation at 2,500  g for 10 min to isolate soluble cytosolic and nuclear pellet fractions. The
nuclear pellet was washed twice with low-salt buffer and then treated with MNase (Thermo Fisher
Scientific) in the presence of 1 mM CaCl2 for 10 min at 37°C followed by addition of EDTA to stop MNase
digestion. The samples were centrifuged again to isolate MNAse-soluble chromatin fractions and
MNAse-insoluble pellet fractions. The MNAse-insoluble pellet fractions were dissolved in high-salt buffer
(50 mM HEPES-NaOH [pH 7.5], 20% glycerol, 420 mM NaCl, 0.4% NP-40) for 30 min with rocking at 4°C.
Finally, the high-salt fraction was isolated by centrifugation. Soluble fractions were combined for
immunoprecipitation with anti-HA or anti-MYC antibodies coupled with magnetic Dynabeads per the
instructions of the manufacturer (Thermo Fisher). Immunoprecipitated proteins on the beads were boiled
in SDS sample buffer for 5 min and processed for Western blotting or proteomics analysis. All buffers
used in the protocol were supplemented with Roche cOmplete Mini EDTA-free protease inhibitor cocktail
and 1 mM phenylmethylsulfonyl fluoride (PMSF).
Mass spectrometry of the AP2IX-4 complex. Sample preparation and mass spectrometry analysis
were performed as previously described (38). Briefly, immunoprecipitated samples on Dynabeads were
resuspended in 8 M urea for denaturation, reduced, and alkylated. The alkylated samples were digested
with endoproteinase LysC and trypsin gold (Promega) at 37°C overnight. The digested peptides were
purified with a spin column (Pierce), followed by injection into a C18 reversed-phase trap column (3 m
pore size). The peptides were then separated on an EASY-Spray 15-cm reversed-phase analytical column
(Thermo Fisher) (2 m pore size). Peptides were separated on acetonitrile (2% to 25% gradient for
90 min) in front of a Velos Pro Orbitrap mass spectrometer in data-dependent acquisition mode. Liquid
chromatography/mass spectrometry (LC/MS) data were obtained using Proteome discoverer software
and searched against the ToxoDB database. The list of 136 total proteins identified was generated with
Scaffold proteome software. Bioinformatics analysis was performed as described previously (17). Briefly,
the filters used for hit selection from Scaffold software were as follows: minimum number of peptides,
2; protein threshold, 99.9%; peptide threshold, 95%; false-discovery rate (FDR), 0%. SAINT (Significance
Analysis of INTeractome) analysis of interactome data was performed as previously described (38).
Statistical analysis. GraphPad Prism software was used for statistical analyses. SAINTexpress soft-
ware was used for SAINT analysis.
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